America’s Pharmaceutical Supply and Payment Chain Collaborating to Promote Undisrupted Patient Access to Medications

(Washington, D.C.) — Today, representative organizations of America’s pharmaceutical supply and payment chain, including prescription and over-the-counter brand and generic manufacturers; wholesalers; retail, specialty, and managed care, pharmacies; health insurance providers and other payers; pharmacists in hospitals and health systems; and pharmacy benefit managers, released new policy principles to promote undisrupted patient access to medications during...

Keep Reading

COVID-19: How PBMs Are Helping Patients and Health Plans

Keep Reading

Just the Facts: Pharmacy Direct and Indirect Remuneration Increases Value and Improves Quality

During the Energy and Commerce Health Subcommittee hearing on “The Fiscal Year 2021 HHS Budget and Oversight of the Coronavirus Outbreak” several inaccurate remarks were made on pharmacy direct and indirect remuneration (DIR). What is Pharmacy DIR? Pharmacy benefit managers (PBMs) and Part D plan sponsors use pharmacy DIR to create high-quality, value-based pharmacy networks,...

Keep Reading

PCMA: Inaccurate Kaiser Health News Video Sides with Drug Makers

The video (“Little Known Middlemen Who Save $$ On Medicines — But Maybe Not For You”) includes basic inaccuracies and confuses the roles of drug companies, wholesalers, drugstores, payors, and PBMs.

Keep Reading

High drug prices likely to continue in 2017, VCs say

Venrock partners Bob Kocher and Bryan Roberts predict that drug prices will continue to rise as copayment coupons desensitize patients to high prices; more drugstores will close as online shopping grows; and insurance premiums will rise, driven by regulatory uncertainty, high drug prices and hospital market power.

Keep Reading

GSK says experimental 2-drug combo suppresses HIV

GlaxoSmithKline division ViiV Healthcare said a pill that combines dolutegravir and Johnson & Johnson’s rilpivirine suppressed HIV as well as three- and four-drug combinations in Phase III clinical trial results.

Keep Reading

Physicians support outcomes-based biopharmaceuticals pricing

Physicians voiced their support of outcomes-based pricing for experimental and expensive biopharmaceutical drugs in an Ideas and Opinions article published online in the Annals of Internal Medicine. The authors, led by Dr. Daniel Blumenthal of Massachusetts General Hospital, note that outcomes-based pricing could increase access to treatments while keeping costs down and “would compel manufacturers...

Keep Reading

21st Century Cures bills go beyond funding medical research

The package of bills known as the 21st Century Cures Act is on its way to the Senate after passing a House vote, and the legislation contains some little-discussed provisions that affect health insurance and Medicare. For example, some employers would be allowed to give employees money to buy their own health insurance plans, and...

Keep Reading

New Survey: Consumers Hold Drug Companies Responsible for High Prices and Out-of-Pocket Costs

(Washington, D.C.) — A new national survey finds most voters blame drug companies not only for high drug prices, but also for out-of-pocket costs. The findings undermine the drug industry’s $100 million PR campaign to blame higher costs on employers, unions, health plans and the pharmacy benefit managers (PBMs) they use to negotiate discounts on...

Keep Reading

Trump’s pick for HHS secretary has plans for replacing ACA

Rep. Tom Price, R-Ga., who is President-elect Donald Trump’s choice to lead HHS, has repeatedly proposed legislation to replace the Affordable Care Act. His plans include offering consumers fixed tax credits to buy health insurance, expanding health savings accounts, capping employer tax deductions for health insurance, creating state-run high-risk pools and allowing some coverage restrictions...

Keep Reading